Department of Research and Epidemiology, The Canadian College of Naturopathic Medicine, Toronto, Ontario, Canada.
PLoS One. 2011;6(11):e26259. doi: 10.1371/journal.pone.0026259. Epub 2011 Nov 4.
Selenium is a natural health product widely used in the treatment and prevention of lung cancers, but large chemoprevention trials have yielded conflicting results. We conducted a systematic review of selenium for lung cancers, and assessed potential interactions with conventional therapies.
Two independent reviewers searched six databases from inception to March 2009 for evidence pertaining to the safety and efficacy of selenium for lung cancers. Pubmed and EMBASE were searched to October 2009 for evidence on interactions with chemo- or radiation-therapy. In the efficacy analysis there were nine reports of five RCTs and two biomarker-based studies, 29 reports of 26 observational studies, and 41 preclinical studies. Fifteen human studies, one case report, and 36 preclinical studies were included in the interactions analysis. Based on available evidence, there appears to be a different chemopreventive effect dependent on baseline selenium status, such that selenium supplementation may reduce risk of lung cancers in populations with lower baseline selenium status (serum<106 ng/mL), but increase risk of lung cancers in those with higher selenium (≥ 121.6 ng/mL). Pooling data from two trials yielded no impact to odds of lung cancer, OR 0.93 (95% confidence interval 0.61-1.43); other cancers that were the primary endpoints of these trials, OR 1.51 (95%CI 0.70-3.24); and all-cause-death, OR 0.93 (95%CI 0.79-1.10). In the treatment of lung cancers, selenium may reduce cisplatin-induced nephrotoxicity and side effects associated with radiation therapy.
Selenium may be effective for lung cancer prevention among individuals with lower selenium status, but at present should not be used as a general strategy for lung cancer prevention. Although promising, more evidence on the ability of selenium to reduce cisplatin and radiation therapy toxicity is required to ensure that therapeutic efficacy is maintained before any broad clinical recommendations can be made in this context.
硒是一种广泛用于治疗和预防肺癌的天然保健品,但大型化学预防试验的结果却相互矛盾。我们对硒治疗肺癌的作用进行了系统评价,并评估了其与常规治疗的潜在相互作用。
两名独立的审查员从建立数据库起至 2009 年 3 月,在六个数据库中搜索了与硒治疗肺癌的安全性和疗效相关的证据。为寻找硒与化疗或放疗相互作用的证据,对 Pubmed 和 EMBASE 进行了截至 2009 年 10 月的检索。在疗效分析中,有 9 项报告来自 5 项 RCT 和 2 项基于生物标志物的研究,有 29 项报告来自 26 项观察性研究,还有 41 项临床前研究。在相互作用分析中,纳入了 15 项人体研究、1 项病例报告和 36 项临床前研究。基于现有证据,似乎存在着不同的化学预防效果,这取决于基线硒状态,即硒补充剂可能会降低低基线硒状态(血清<106ng/ml)人群中肺癌的风险,但可能会增加高基线硒状态(≥121.6ng/ml)人群中肺癌的风险。两项试验的数据合并后,对肺癌的几率没有影响,比值比(OR)为 0.93(95%置信区间 0.61-1.43);这些试验的主要终点是其他癌症,OR 为 1.51(95%CI 0.70-3.24);全因死亡,OR 为 0.93(95%CI 0.79-1.10)。在治疗肺癌方面,硒可能会降低顺铂引起的肾毒性和与放射治疗相关的副作用。
对于硒状态较低的个体,硒可能对肺癌预防有效,但目前不应将其作为预防肺癌的一般策略。尽管有希望,但需要更多证据来证明硒降低顺铂和放疗毒性的能力,以确保在这方面提出任何广泛的临床建议之前,治疗效果得以维持。